Diagenode Launches Novel CRISPR/Cas9 Monoclonal Antibody

New CRISPR/Cas9 Antibody Validated for All Major Applications Including Immunoprecipitation, Immunofluorescence, and Immunoblotting

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The new CRISPR/Cas9 antibody is superior to epitope-tagged antibodies as it provides a much higher sensitivity.

Denville, NJ (PRWEB) August 08, 2014

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched the industry’s first monoclonal antibody targeting CRISPR/Cas9. The antibody has been extensively validated for a number of applications including western blotting, immunofluorescence to determine protein localization, and immunoprecipitation applications such as chromatin immunoprecipitation.

The CRISPR/Cas system has been most commonly used for gene editing such as in gene silencing or changing specific genes in both bacterial systems and eukaryotic systems. In addition, Cas9 can also be used to mediate upregulation or downregulation of specific endogenous genes or to alter histone modifications or DNA methylation. The new monoclonal antibody will allow researchers to supplement their CRISPR/Cas studies.

“Diagenode has been a long time supplier of highly sensitive and specific validated epigenetic antibodies. We are pleased to offer the first monoclonal CRISPR/Cas9 antibody for epigenetic applications as well as a variety of other validated methods,” stated Didier Allaer, CEO of Diagenode. “The new CRISPR/Cas9 antibody is superior to epitope-tagged antibodies as it provides a much higher sensitivity.”

More information on Diagenode’s CRISPR/Cas9 antibody validation and other epigenetic-focused antibodies can be found at http://www.diagenode.com/en/landing-pages/CAS9-monoclonal-antibody.php.

About Diagenode, Inc.:
Diagenode is a leading provider of complete solutions for epigenetic research. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique, full automation system, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.


Contact

  • Didier Allaer
    Diagenode, Inc.
    1 862 209 4680
    Email
Follow us on: Contact's Facebook